SIO Gene Therapies Inc. Reports Net Loss of $15.5 Million in Nine Months Ended December 31, 2022

SIO Gene Therapies Inc.(SIOX), a leading biotechnology compa ny focused on developing gene therapies for neurological disorders, has released its unaudited condensed consolidated financial statements for the nine months ended December 31, 2022. The company reported a net loss of $15.5 million during this period, highlighting the challenges it faced in advancing its innovative treatments. The financial statements also reveal the company's revenue and provide insights into its current financial position.

Revenue and Financial Highlights

During the nine months ended December 31, 2022, SIO Gene Therapies Inc. generated revenue, but the specific amount was not disclosed in the provided financial data. Despite the company's efforts, the revenue figures indicate a challenging period for SIO Gene Therapies Inc. as it continues its research and development activities.

Net Losses in Nine Months Ended December 31, 2022